Literature DB >> 29707316

Single nucleotide polymorphisms of casitas B-lineage lymphoma proto-oncogene-b predict outcomes of patients with advanced non-small cell lung cancer after first-line platinum based doublet chemotherapy.

Peng Li1,2,3, Hong-Liang Liu4, Zhi-Qiang Zhang1,2, Xiao-Dong Lv5, Yu-Xi Chang6, Hui-Juan Wang3, Jie Ma6, Zhi-Yong Ma3, Xiu-Juan Qu1,2, Yue-E Teng1,2.   

Abstract

BACKGROUND: Casitas B-lineage lymphoma proto-oncogene-b (CBLB) influences the threshold of T cell activation and controlling peripheral T cell tolerance. In the present study, we hypothesize that potentially functional single nucleotide polymorphisms (SNPs) in CBLB are associated with clinical outcomes in patients advanced non-small cell lung cancer (NSCLC) treated with the first-line chemotherapy.
METHODS: We genotyped three SNPs (rs2305035, rs3772534 and rs9657904) at CBLB in 116 advanced NSCLC patients with progression free survival (PFS) data and 133 advanced NSCLC patients with overall survival (OS) data, and we assessed their associations, 95% confidence interval (CI), with clinical outcomes by using Cox proportional hazards regression analyses. In silico functional analysis was also performed for the SNPs under investigation.
RESULTS: We found that associations between the three SNPs and PFS/OS were not significant in the overall NSCLC patients. The rs2305035 AA genotype was associated with a worse PFS in female patients and those of non-smokers or light smokers (95% CI, 1.14-11.81, P=0.030; 95% CI, 1.42-10.24, P=0.008; and 95% CI, 1.39-9.93, P=0.009; respectively), compared with the GG+AA genotypes. We also found that the rs9657904 CC genotype was significantly associated with a worse OS than TT + TC genotypes in male advanced NSCLC patients. Further in silico functional analysis revealed that the rs965704 T allele was significantly associated with lower mRNA expression levels of the CBLB gene.
CONCLUSIONS: Our findings identified two CBLB SNPs (rs2305035 and rs9657904) that were significantly associated with PFS and OS in several subgroups of Chinese advanced NSCLC patients after the first-line chemotherapy.

Entities:  

Keywords:  Non-small cell lung cancer (NSCLC); casitas B-lineage lymphoma proto-oncogene-b (CBLB); first-line platinum based doublet chemotherapy; single nucleotide polymorphism (SNP)

Year:  2018        PMID: 29707316      PMCID: PMC5906294          DOI: 10.21037/jtd.2018.02.31

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  40 in total

1.  Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells.

Authors:  D Fang; H Y Wang; N Fang; Y Altman; C Elly; Y C Liu
Journal:  J Biol Chem       Date:  2000-11-21       Impact factor: 5.157

2.  Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis.

Authors:  Serena Sanna; Maristella Pitzalis; Magdalena Zoledziewska; Ilenia Zara; Carlo Sidore; Raffaele Murru; Michael B Whalen; Fabio Busonero; Andrea Maschio; Gianna Costa; Maria Cristina Melis; Francesca Deidda; Fausto Poddie; Laura Morelli; Gabriele Farina; Yun Li; Mariano Dei; Sandra Lai; Antonella Mulas; Gianmauro Cuccuru; Eleonora Porcu; Liming Liang; Patrizia Zavattari; Loredana Moi; Elisa Deriu; M Francesca Urru; Michele Bajorek; Maria Anna Satta; Eleonora Cocco; Paola Ferrigno; Stefano Sotgiu; Maura Pugliatti; Sebastiano Traccis; Andrea Angius; Maurizio Melis; Giulio Rosati; Gonçalo R Abecasis; Manuela Uda; Maria Giovanna Marrosu; David Schlessinger; Francesco Cucca
Journal:  Nat Genet       Date:  2010-05-09       Impact factor: 38.330

3.  Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CBLB [correction of CLBL] genes.

Authors:  Jezabel Varadé; Manuel Comabella; Miguel A Ortiz; Rafael Arroyo; Oscar Fernández; M Jesús Pinto-Medel; María Fedetz; Guillermo Izquierdo; Miguel Lucas; Carlos López Gómez; Antonio Catalá Rabasa; Antonio Alcina; Fuencisla Matesanz; Iraide Alloza; Alfredo Antigüedad; María García-Barcina; David Otaegui; Javier Olascoaga; Albert Saiz; Yolanda Blanco; Xavier Montalbán; Koen Vandenbroeck; Elena Urcelay
Journal:  Mult Scler       Date:  2011-12-22       Impact factor: 6.312

4.  Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice.

Authors:  Ingunn M Stromnes; Joseph N Blattman; Xiaoxia Tan; Sara Jeevanjee; Hua Gu; Philip D Greenberg
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

5.  Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor.

Authors:  Kyriakos Neofytou; Elizabeth C Smyth; Alexandros Giakoustidis; Aamir Z Khan; David Cunningham; Satvinder Mudan
Journal:  Med Oncol       Date:  2014-09-14       Impact factor: 3.064

6.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

7.  Ablation of Cbl-b provides protection against transplanted and spontaneous tumors.

Authors:  Jeffrey Y Chiang; Ihn Kyung Jang; Richard Hodes; Hua Gu
Journal:  J Clin Invest       Date:  2007-03-15       Impact factor: 14.808

8.  Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.

Authors:  Stephanie L Goff; Mark E Dudley; Deborah E Citrin; Robert P Somerville; John R Wunderlich; David N Danforth; Daniel A Zlott; James C Yang; Richard M Sherry; Udai S Kammula; Christopher A Klebanoff; Marybeth S Hughes; Nicholas P Restifo; Michelle M Langhan; Thomas E Shelton; Lily Lu; Mei Li M Kwong; Sadia Ilyas; Nicholas D Klemen; Eden C Payabyab; Kathleen E Morton; Mary Ann Toomey; Seth M Steinberg; Donald E White; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2016-05-23       Impact factor: 44.544

Review 9.  Modulation of Immune Cell Functions by the E3 Ligase Cbl-b.

Authors:  Christina Lutz-Nicoladoni; Dominik Wolf; Sieghart Sopper
Journal:  Front Oncol       Date:  2015-03-11       Impact factor: 6.244

10.  The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.

Authors:  Magdalena Paolino; Axel Choidas; Stephanie Wallner; Blanka Pranjic; Iris Uribesalgo; Stefanie Loeser; Amanda M Jamieson; Wallace Y Langdon; Fumiyo Ikeda; Juan Pablo Fededa; Shane J Cronin; Roberto Nitsch; Carsten Schultz-Fademrecht; Jan Eickhoff; Sascha Menninger; Anke Unger; Robert Torka; Thomas Gruber; Reinhard Hinterleitner; Gottfried Baier; Dominik Wolf; Axel Ullrich; Bert M Klebl; Josef M Penninger
Journal:  Nature       Date:  2014-02-19       Impact factor: 49.962

View more
  1 in total

Review 1.  E3 ubiquitin ligase Casitas B lineage lymphoma-b and its potential therapeutic implications for immunotherapy.

Authors:  D Jafari; M J Mousavi; S Keshavarz Shahbaz; L Jafarzadeh; S Tahmasebi; J Spoor; A Esmaeilzadeh
Journal:  Clin Exp Immunol       Date:  2021-01-10       Impact factor: 5.732

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.